Vincent Ribrag attended the University of Science and Medical School of Paris Xl between 1978 and 1985. In 1990-1991 he obtained his Maitrise of Science et Biologie Médicale in Molecular Biology, with Professor JC Kaplan. In the years 1990-1992 he also received his Diplôme d’Études Approfondies in molecular and cellular pharmacology at the Pierre et Marie Curie (Paris Vl) Univeristy with Professor Ascher. He obtained his Diplôme d’Études Secondaires in Medical Oncology and discussed a thesis (silver medal) at the Paris Xl Faculty of Medicine entitled “VIP (etoposide,ifosfamide, cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin’s disease.” Dr Ribrag is Assistant at the oncology centers of the Gustave-Roussy lnstitute and has been nominated head of the multidisciplinary committee and head of the early drug program (DITEP) in Gustave Roussy.
Among numerous experimental activities, he counts a Laboratoire in clinical pharmacology (URA 147 CNRS, U-140 INSERM) with Dr A Gouyette; works in enzymology (Cancer Res, 52: 6567€575, 1992., Garcinogenesis 14: 1279-1283, 1993., Leukemia Res 18: 829-835, 1994., leukemia and lymphoma 18: 303-310, 1995.); the ICGM: INSERM U-363 at the Hôpital Cochin in Paris (1993-1994). Enzymology and drug resistance works in leukemia (Leukemia 10:1944-1949, 1996., Anticancer Res. 17:4647-4652, 1997); the Unité INSERM U 1170: Animal MCL models and drug discovery.
Dr Ribrag is member of several international cancer societies, namely the American Association for Cancer Research (AACR), the American ociety of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the Société Française de Greffe de Moelle (SFGM), the Société Française d’Hématologie (SFH), the Groupe Français des Myélodysplasies (GFM) and French intergroup on myeloproliferative diseases (FIM).
He is also part of the Lysa Scientific and Administrative Committees and of the European Scientific Committee of the Mantle Cell Lymphoma study group since 2001 and associated Head of early trials with Martin Dreyling. He is part of the board phase I trials new network within the Lysa.